1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for individuals in West Okoboji battling with opioid abuse and addiction is called opioid maintenance therapy. Licensed clinics and doctors are certified to administer specific medications to opioid dependent individuals, many of which are opioids also and are addictive. In low doses however, the user does not experience high feelings and also doesn't experience severe cravings and is not in opioid withdrawal. Methadone is the first med administered for this sole purpose, but there are alternative choices to select from.
Methadone is an opiate and can be taken at an outpatient medical center certified to dispense the med, which is taken daily in liquid or pill form. The cost of the drug is about under $200 per month. Buprenorphine is also an opiate based med, and is in pill form often taken every other day. But different from Methadone that is only be administered in highly structured clinics, Buprenorphine can be prescribed and administered in doctor's offices. The price monthly of buprenorphine is approximately $300.00 /month for the generic of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, which is a drug that reverses the effects of opiates. An individual consuming this formulation, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and costs approximately $450 /month. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other drugs mentioned here it's an opiate blocker and isn't an opioid. A person has the choice to take this drug as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents an individual from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 a month.
For All Alcohol and Drug Treatment Facilities In West Okoboji, Click Here.
